Pharmaceutical Germany-headquartered Qiagen has entered into an agreement to acquire STAT-Dx, a privately-held Spanish company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven Qiagen chemistries. 1 February 2018